Angie You Biography and Net Worth

Director of Oric Pharmaceuticals

Dr. You has served as a member of our board of directors since November 2021. She is currently the Chief Executive Officer of Architect Therapeutics. Prior to Architect, Dr. You served as Chief Executive Officer of Amunix Pharmaceuticals, from December 2018 to January 2022 upon which Amunix was acquired by Sanofi S.A. Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology from 2014 to 2018, where she helped the company through a successful initial public offering and led the company’s strategic and transactional business and commercial efforts. Prior to Sierra Oncology, Dr. You served as Chief Business Officer of Aragon Pharmaceuticals from 2010 through its acquisition by Johnson & Johnson in 2013.

In previous roles, Dr. You served as Chief Business Officer at Synosia Therapeutics and Ren Pharmaceuticals. Before joining Ren Pharmaceuticals, Dr. You focused on new company formation at Venrock Ventures. Dr. You earned a Ph.D. in Biochemistry from Harvard University and a A.B. in Chemistry from Harvard College.

What is Angie You's net worth?: The estimated net worth of Angie You is at least $317.10 thousand as of June 23rd, 2025. Dr. You owns 28,000 shares of Oric Pharmaceuticals stock worth more than $317,100 as of December 4th. This net worth estimate does not reflect any other investments that Dr. You may own. Learn More about Angie You's net worth.
How do I contact Angie You?: The corporate mailing address for Dr. You and other Oric Pharmaceuticals executives is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. Oric Pharmaceuticals can also be reached via phone at 650-388-5600 and via email at [email protected]. Learn More on Angie You's contact information.
Has Angie You been buying or selling shares of Oric Pharmaceuticals?: Angie You has not been actively trading shares of Oric Pharmaceuticals during the past quarter. Most recently, on Monday, June 23rd, Angie You bought 1,403 shares of Oric Pharmaceuticals stock. The stock was acquired at an average cost of $9.43 per share, with a total value of $13,230.29. Following the completion of the transaction, the director now directly owns 28,000 shares of the company's stock, valued at $264,040. Learn More on Angie You's trading history.
Who are Oric Pharmaceuticals' active insiders?: Oric Pharmaceuticals' insider roster includes Jacob Chacko (CEO), Carl Gordon (Director), Richard Heyman (Director), Pratik Multani (Chief Medical Officer), Dominic Piscitelli (CFO), Richard Scheller (Director), and Angie You (Director). Learn More on Oric Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Oric Pharmaceuticals?: During the last twelve months, Oric Pharmaceuticals insiders bought shares 2 times. They purchased a total of 28,000 shares worth more than $262,976.12. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 343,361 shares worth more than $3,791,740.79. The most recent insider tranaction occured on October, 6th when CFO Dominic Piscitelli sold 11,000 shares worth more than $159,720.00. Insiders at Oric Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Oric Pharmaceuticals.
Information on this page was last updated on 10/6/2025.

Angie You Insider Trading History at Oric Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/23/2025	Buy	1,403	$9.43	$13,230.29	28,000
6/20/2025	Buy	26,597	$9.39	$249,745.83	26,597

Angie You Buying and Selling Activity at Oric Pharmaceuticals

Oric Pharmaceuticals Company Overview

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Today's Range

Now: $11.39

$10.72

$11.54

50 Day Range

MA: $12.44

$10.65

$14.41

2 Week Range

Now: $11.39

$3.90

$14.93

Volume

1,266,442 shs

Average Volume

1,130,416 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32